GREATER THAN the sum of its parts. That, in a nutshell, is how Albert Bourla, the newish chief executive of Pfizer, described the merger of the giant drugmaker’s stodgy but profitable off-patent division, Upjohn, and Mylan, a big but struggling generic-drug firm. The all-stock transaction, announced on July 29th, would create the world’s largest generics…